Login to Your Account

Mitsubishi Tanabe's ALS drug wins nod ahead of PDUFA date

By Jennifer Boggs
Managing Editor

Monday, May 8, 2017

The FDA has joined Japanese and South Korean regulators in approving edaravone, an intravenously administered antioxidant free radical scavenger, for treating ALS, with its late Friday approval coming more than a month ahead of the PDUFA date.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription